<DOC>
	<DOCNO>NCT00452348</DOCNO>
	<brief_summary>This purpose study show superiority long term safety efficacy add long act beta agonist ( salmeterol ) constant dose inhale corticosteroid ( fluticasone propionate ) symptomatic subject asthma . The 12-month assessment asthma control provide key information efficacy safety combination therapy . The safety measure assessment adverse event</brief_summary>
	<brief_title>A 12-Month Study Comparing Fluticasone Propionate/Salmeterol ( ADVAIR ) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate ( FLOVENT ) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Subjects eligible enrollment study must meet following criterion : 1 . Consent : A sign date write informed consent must obtain subject and/or subject 's legally acceptable representative prior study participation . 2 . Type Subject : Outpatient 3 . Gender : Male female Females eligible participate currently nonpregnant nonlactating . A female eligible enter participate study : 1. nonchildbearing potential ; OR 2. childbearing potential negative urinary pregnancy test Screening ( Visit 1 specify Appendix 1 ) agrees take contraceptive precaution ( include abstinence ) adequate prevent pregnancy study . Acceptable method contraception [ Hatcher , 2004 ] : Abstinence oral contraceptive ( either combine progestogen ) injectable progestogen implant levonorgestrel estrogenic vaginal ring percutaneous contraceptive device intrauterine device ( IUD ) intrauterine system ( IUS ) publish data show low expected failure rate le 1 % per year male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study sole sexual partner female subject double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent 1 . Age : A subject must 12 year age Visit 1 ( screen ) . 2 . Asthma Diagnosis : A documented diagnosis persistent asthma , least six month , define following American Thoracic Society definition : Asthma clinical syndrome characterize increased responsiveness airway variety stimulus . The major symptom asthma episode dyspnea , wheeze , cough , may vary mild almost undetectable severe unremitting ( status asthmaticus ) . The primary physiological manifestation hyperresponsiveness variable airway obstruction . This take form spontaneous fluctuation severity obstruction , substantial improvement severity obstruction follow bronchodilator corticosteroid , increase obstruction cause drug stimuli [ American Thoracic Society , 1987 ] . 1 . Asthma Medication History : A subject must use low medium dose ICS ( Table 1 ) OR combination controller medication ( Table 2 ) , contain low ( total daily ) dose ICS ( define Table 1 ) least 4 week precede screening . Table 1 ( ICS Dosage Table ) Inhaled Corticosteroid ( Dosage ( mcg/day ) ) ( LowMedium ) Beclomethasone dipropionate CFC ( 168 = 504 &gt; 504 = 840 ) Beclomethasone dipropionate HFA ( 80 = 240 &gt; 240 = 640 ) Triamcinolone acetonide ( 400 = 1000 &gt; 1000 = 2000 ) Flunisolide ( 500 = 1000 &gt; 1000 = 2000 ) Fluticasone propionate inhalation aerosol ( 176 = 220 &gt; 220 = 440 ) Fluticasone propionate inhalation powder ( 100 = 250 &gt; 250 = 500 ) Budesonide1 ( 200 = 600 &gt; 600 =1200 ) Mometasone ( 200 = 400 &gt; 400 = 800 ) Ciclesonide ( 80 = 160 &gt; 160 = 320 ) 1.Respules allow dosage 250500mcg/day . Table 2 ( Asthma Controller Medications ) Asthma Controller Medication ( ) Low dose ICS + Leukotriene modifier Low dose ICS + Theophylline product Low Dose ICS + Inhaled anticholinergic combination product ( e.g. , Atrovent Combivent ) Low Dose ICS + Long act inhale anticholinergic ( e.g . Spiriva ) Low dose ICS+ long act beta agonist combination product contain low dose ICS longacting betaagonists ( e.g . ADVAIR™/SERETIDE™1 100/50 mcg BID Symbicort 160/9 mcg BID ( i.e 80/4.5 mcg two inhalation BID ) 1.ADVAIR/SERETIDE =250/50 mcg BID Symbicort 320/9 mcg BID ( i.e 160/4.5 mcg two inhalation BID ) permit . 1 . Pulmonary function : A prealbuterol ( salbutamol ) FEV1 50 % 85 % predict normal value screening ( Visit 1 ) withholding asthma medication detail protocol ( Section 6.8.1 ) . Predicted FEV1 base National Health Nutrition Examination Survey ( NHANES III ) predict normal value age 8 year old [ Hankinson , 1999 ] . 2 . Reversibility : An increase FEV1 12 % prealbuterol ( salbutamol ) FEV1 within 30 minute inhalation 24 puff albuterol ( salbutamol ) . Historical documentation reversibility permit . 3 . Asthma symptom criterion : Each subject must experience asthma symptom require albuterol ( salbutamol ) use within 4 week precede screening ( Visit 1 ) . Specific information regard warning , precaution , contraindication , adverse event , pertinent information investigational product may impact subject eligibility provide IB product label . Subjects meet follow criterion must enrol study : 1.LifeThreatening Asthma : A subject must lifethreatening asthma . Lifethreatening asthma define protocol history significant asthma episode ( ) require intubation associate hypercapnia , respiratory arrest , hypoxic seizure , asthmarelated syncopal episode ( ) within 12 month prior screen ( Visit 1 ) . 2.Worsening Asthma : A subject must experience worsen asthma involve ER visit , hospitalization use oral/parenteral corticosteroid within 4 week screen ( Visit 1 ) . 3.Intermittent , Seasonal , ExerciseInduced Asthma Alone : Subjects intermittent seasonal exerciseinduced asthma exclude participation study . 4.Concurrent Respiratory Disease : A subject must current evidence pneumonia , pneumothorax , atelectasis , pulmonary fibrotic disease , chronic bronchitis , emphysema , chronic obstructive pulmonary disease , respiratory abnormality asthma . 5.Concurrent Conditions/Diseases : A subject historical current evidence clinically significant , comorbid uncontrolled condition disease state , opinion investigator , would put safety subject risk study participation would confound interpretation result condition/disease exacerbate study . The list exclude conditions/diseases include , limited : congestive heart failure know aortic aneurysm clinically significant coronary clinically significant cardiac arrhythmia heart disease stroke within 3 month screen ( Visit 1 ) uncontrolled hypertension coronary artery disease hematologic , hepatic , renal disease cystic fibrosis poorly control peptic ulcer dyspnea cause asthma gastroesophageal reflux disease ( GERD ) control pharmacotherapy may causing/contributing subject 's respiratory symptom thyrotoxicosis hypokalemia immunologic compromise current malignancy1 tuberculosis ( current quiescent ) Cushing 's Addison 's disease pneumonia , pneumothorax , chronic bronchitis atelectasis uncontrolled diabetes mellitus recent history drug alcohol abuse 1.history malignancy acceptable subject remission one year prior screening ( Visit 1 ; remission = treatment malignancy 12 month prior screen [ Visit 1 ] ) 1 . Drug Allergy : A subject must immediate delayed hypersensitivity beta2agonist ; sympathomimetic drug ; intranasal ; inhale systemic corticosteroid therapy ; lactose ; severe milk protein allergy . 2 . Respiratory Tract Infections : A subject must sinus , middle ear , oropharyngeal , upper low respiratory tract infection symptom resolve least 7 day immediately precede screen ( Visit 1 ) . 3 . Asthma Medications : Asthma medication list must use prior screen ( Visit 1 ) require exclusion period indicate : Medication ( Exclusion Period Prior screening ( Visit 1 ) ) Oral parenteral systemic corticosteroid ( 4 week ) Omalizumab ( Xolair ) ( 6 month ) 1 . Concurrent Medications : A subject must concurrent use follow medication interact study drug use study , may affect course asthma interact sympathomimetic amine , : betaadrenergic receptor block agent monoamine oxidase ( MAO ) inhibitor tricyclic antidepressant ritonavir ketoconazole 2 . Concurrent use asthma medication : Concurrent use asthma medication ( protocol define study rescue medication oral/parenteral corticosteroid ) prohibit study . 3 . Concomitant use leukotriene modifier ( LTM ) allergy prohibit . A subject must LTM treatment nasal allergy require regular maintenance therapy . Substitution antihistamine permit . 4 . Immunosuppressive Medications : A subject must use , require use , immunosuppressive medication study . 5 . Immunotherapy treatment allergy allow study unless subject use constant dose 4 week prior Screening ( Visit 1 ) dose continue throughout study . 6 . Tobacco Use : &gt; 10 pack year history use tobacco product within 1 year screening ( Visit 1 ) . This include cigarette , cigar , pipe , chew tobacco , snuff . 7 . Questionable Validity Consent : A subject must infirmity disability would limit subject 's consent . 8 . Positive Pregnancy Test ( female menarche ) : A current positive pregnancy test . 9 . Investigational Medications : A subject must use investigational drug within 30 day screen ( Visit 1 ) . 10 . Site Affiliation : A subject may participate he/she participate investigator , subinvestigator , study coordinator , employee participate investigator way associate administration study . Immediate family member individual also exclude . 11 . Compliance Study Requirements : A subject may participate , opinion investigator , present anticipated circumstance prohibit subject compliant study visit procedure ( e.g . geographic location prohibit subject require clinic visit schedule ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>FLOVENT</keyword>
	<keyword>fluticasone</keyword>
	<keyword>12 month</keyword>
	<keyword>salmeterol</keyword>
	<keyword>asthma</keyword>
	<keyword>ADVAIR</keyword>
</DOC>